Sitaxsentan for the treatment of pulmonary arterial hypertension

Reda E. Girgis, Richard A.F. Dixon

Research output: Contribution to journalArticlepeer-review


Pulmonary arterial hypertension (PAH) is a life-threatening, progressive condition that eventually leads to right heart failure. Endothelin receptor antagonists (ETRAs) have been shown to be a safe and efficacious treatment for PAH. Sitaxsentan is a highly selective oral ETRA that, in clinical trials, has demonstrated significant improvements in exercise capacity, functional class and pulmonary hemodynamics in PAH. Sitaxsentan has been shown to be a well tolerated and effective agent with a durable response for the treatment of PAH, and is associated with a low incidence of liver toxicity.

Original languageEnglish (US)
Pages (from-to)377-385
Number of pages9
JournalFuture Cardiology
Issue number4
StatePublished - Jul 1 2007


  • Endothelin
  • Endothelin A
  • Endothelin receptor antagonist
  • Endothelin receptor inhibitor
  • Pulmonary hypertension
  • Sitaxsentan

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Sitaxsentan for the treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this